Chargement en cours...
A Phase II Dose Titration Study of Thalidomide for Cancer-Associated Anorexia
CONTEXT: Sixty-five percent of people with advanced cancer suffer from loss of appetite. Several inflammatory cytokines appear to cause appetite loss in animal models. Thalidomide is an immunomodulatory drug that has been associated with improved appetite in those with HIV infections, and in cancer....
Enregistré dans:
| Publié dans: | J Pain Symptom Manage |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4496946/ https://ncbi.nlm.nih.gov/pubmed/21640548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpainsymman.2011.03.007 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|